<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
    <meta name="keywords" content="Hexo Theme Keep">
    <meta name="description" content="Hexo Theme Keep">
    <meta name="author" content="肿瘤界">
    
    <title>
        
            ASCO23特别篇之研究物语： DUO-O研究--D医生投稿 |
        
        肿瘤界比赛/投稿公示平台
    </title>
    
<link rel="stylesheet" href="/zlj_submit/css/style.css">

    <link rel="shortcut icon" href="/zlj_submit/images/logo.svg">
    
<link rel="stylesheet" href="/zlj_submit/font/css/fontawesome.min.css">

    
<link rel="stylesheet" href="/zlj_submit/font/css/regular.min.css">

    
<link rel="stylesheet" href="/zlj_submit/font/css/solid.min.css">

    
<link rel="stylesheet" href="/zlj_submit/font/css/brands.min.css">

    <script id="hexo-configurations">
    let KEEP = window.KEEP || {}
    KEEP.hexo_config = {"hostname":"cardioio.github.io","root":"/zlj_submit/","language":"en","path":"search.json"}
    KEEP.theme_config = {"toc":{"enable":false,"number":false,"expand_all":false,"init_open":false},"style":{"primary_color":"#0066cc","logo":"/images/logo.svg","favicon":"/images/logo.svg","avatar":"/images/avatar.svg","font_size":null,"font_family":null,"hover":{"shadow":false,"scale":false},"first_screen":{"enable":true,"header_transparent":false,"background_img":"/images/bg.svg","description":"让您的学术观点在肿瘤学知识的海洋中发光.","font_color":null,"hitokoto":false},"scroll":{"progress_bar":false,"percent":false}},"local_search":{"enable":true,"preload":true},"code_copy":{},"code_block":{"tools":{"enable":false,"style":"default"},"highlight_theme":"default"},"side_tools":{},"pjax":{"enable":false},"lazyload":{"enable":false},"comment":{"enable":false,"use":"valine","valine":{"appid":null,"appkey":null,"server_urls":null,"placeholder":null},"gitalk":{"github_id":null,"github_admins":null,"repository":null,"client_id":null,"client_secret":null,"proxy":null},"twikoo":{"env_id":null,"region":null,"version":"1.6.8"},"waline":{"server_url":null,"reaction":false,"version":2}},"post":{"author_label":{"enable":true,"auto":false,"custom_label_list":["医生"]},"word_count":{"enable":true,"wordcount":true,"min2read":true},"img_align":"center","copyright_info":true},"version":"3.6.1"}
    KEEP.language_ago = {"second":"%s seconds ago","minute":"%s minutes ago","hour":"%s hours ago","day":"%s days ago","week":"%s weeks ago","month":"%s months ago","year":"%s years ago"}
    KEEP.language_code_block = {"copy":"Copy code","copied":"Copied","fold":"Fold code block","folded":"Folded"}
    KEEP.language_copy_copyright = {"copy":"Copy copyright info","copied":"Copied","title":"Original article title","author":"Original article author","link":"Original article link"}
  </script>
<meta name="generator" content="Hexo 6.3.0"></head>


<body>
<div class="progress-bar-container">
    

    
</div>


<main class="page-container">

    

    <div class="page-main-content">

        <div class="page-main-content-top">
            
<header class="header-wrapper">

    <div class="header-content">
        <div class="left">
            
                <a class="logo-image" href="/">
                    <img src="/zlj_submit/images/logo.svg">
                </a>
            
            <a class="logo-title" href="/">
               肿瘤界比赛/投稿公示平台
            </a>
        </div>

        <div class="right">
            <div class="pc">
                <ul class="menu-list">
                    
                        <li class="menu-item">
                            <a class=""
                               href="/zlj_submit/"
                            >
                                主页
                            </a>
                        </li>
                    
                        <li class="menu-item">
                            <a class=""
                               href="/zlj_submit/archives"
                            >
                                投稿归档
                            </a>
                        </li>
                    
                    
                        <li class="menu-item search search-popup-trigger">
                            <i class="fas fa-search"></i>
                        </li>
                    
                </ul>
            </div>
            <div class="mobile">
                
                    <div class="icon-item search search-popup-trigger"><i class="fas fa-search"></i></div>
                
                <div class="icon-item menu-bar">
                    <div class="menu-bar-middle"></div>
                </div>
            </div>
        </div>
    </div>

    <div class="header-drawer">
        <ul class="drawer-menu-list">
            
                <li class="drawer-menu-item flex-center">
                    <a class=""
                       href="/zlj_submit/">主页</a>
                </li>
            
                <li class="drawer-menu-item flex-center">
                    <a class=""
                       href="/zlj_submit/archives">投稿归档</a>
                </li>
            
        </ul>
    </div>

    <div class="window-mask"></div>

</header>


        </div>

        <div class="page-main-content-middle">

            <div class="main-content">

                
                    <div class="fade-in-down-animation">
    <div class="post-page-container">
        <div class="article-content-container">

            <div class="article-title">
                <span class="title-hover-animation">ASCO23特别篇之研究物语： DUO-O研究--D医生投稿</span>
            </div>

            
                <div class="article-header">
                    <div class="avatar">
                        <img src="/zlj_submit/images/avatar.svg">
                    </div>
                    <div class="info">
                        <div class="author">
                            <span class="name">肿瘤界</span>
                            
                                <span class="author-label">医生</span>
                            
                        </div>
                        <div class="meta-info">
                            
<div class="article-meta-info">
    <span class="article-date article-meta-item">
        
            <i class="fa-regular fa-calendar-plus"></i>&nbsp;
        
        <span class="pc">2023-07-17 10:13:28</span>
        <span class="mobile">2023-07-17 10:13</span>
    </span>
    
        <span class="article-update-date article-meta-item">
        <i class="fas fa-file-pen"></i>&nbsp;
        <span class="pc">2023-07-17 10:13:28</span>
    </span>
    
    
    

    
    
        <span class="article-wordcount article-meta-item">
            <i class="fas fa-file-word"></i>&nbsp;<span>2.1k Words</span>
        </span>
    
    
        <span class="article-min2read article-meta-item">
            <i class="fas fa-clock"></i>&nbsp;<span>7 Mins</span>
        </span>
    
    
</div>

                        </div>
                    </div>
                </div>
            

            <div class="article-content keep-markdown-body">
                

                <p>#ASCO23特别篇之研究物语： DUO-O研究<br>我在浏览今年ASCO会议的新闻时，<a class="link"   target="_blank" rel="noopener" href="https://www.medscape.com/viewarticle/992740#vp_1" >Medscape<i class="fas fa-external-link-alt"></i></a>上一则标题引起了我的注意：“晚期卵巢癌的巨大进步(Huge Step Forward in Advanced Ovarian Cancer)”。</p>
<h5 id="是什么”巨大进步”呢？"><a href="#是什么”巨大进步”呢？" class="headerlink" title="是什么”巨大进步”呢？"></a>是什么”巨大进步”呢？</h5><p>细看内容，支撑这个巨大进步是DUO-O研究，即一项在化疗+贝伐珠单抗基础上、使用PARP抑制剂联合免疫治疗用于非 BRCA 突变的晚期卵巢癌，使<a class="link"   target="_blank" rel="noopener" href="https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-and-imfinzi-combination-reduced-risk-of-disease-progression-or-death-vs-chemotherapy-and-bevacizumab-in-patients-with-advanced-ovarian-cancer-without-tumour-brca-mutations-in-the-duo-o-phase-iii-trial.html" >疾病进展或死亡风险显著降低了37%<i class="fas fa-external-link-alt"></i></a>。<br>这里面确实有两个较新的点，一是卵巢癌是冷肿瘤，对免疫治疗不敏感；二是PARP抑制剂一般都适用于有BRCA突变的卵巢癌，而对无BRCA突变的卵巢癌也有如此显著的获益，这项叫做DUO-O的研究看来确实是个不小的进步。<br>实际上，<a class="link"   target="_blank" rel="noopener" href="https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.TPS5598" >在2019年的ASCO年会上，DUO-O就已经在会议摘要中亮相了<i class="fas fa-external-link-alt"></i></a>，当时的摘要指出，卵巢癌是个极爱复发的肿瘤，而免疫治疗、抗血管生成抑制剂和 PARP 抑制剂这个三联疗法，具有协同抗肿瘤作用，也算是卵巢癌现阶段最强新药组合了，能否实现“三英胜吕布”的效果是DUO-O研究的主要目的。此外就是描述了研究方法，没有结果，本次会议则揭示了中期分析结果。</p>
<h5 id="在正式进入研究之前，我们先来简单说两句PARP的机制，因为这个缩写隐藏了太多的细节："><a href="#在正式进入研究之前，我们先来简单说两句PARP的机制，因为这个缩写隐藏了太多的细节：" class="headerlink" title="在正式进入研究之前，我们先来简单说两句PARP的机制，因为这个缩写隐藏了太多的细节："></a>在正式进入研究之前，我们先来简单说两句PARP的机制，因为这个缩写隐藏了太多的细节：</h5><p>PARP的全称是聚ADP核糖聚合酶 (Poly ADP-ribose Polymerase) ，看名字挺复杂的，也不好懂。<br>比如第一个单词poly是什么意思，是指很多个酶吗？的确是的，因为ADP核糖聚合酶需要多个聚集在一起才能被激活，所以PARP的第一个字母P就是指的多个ADP核糖。<br>后面的ADP核糖就是指PARP的底物，PARP催化聚合的就是这个东西，把多个ADP-核糖串成ADP-核糖链，你可以把这个核糖链条理解为建筑公司盖楼时的脚手架，在断裂的DNA处形成一个脚手架，一是保护断裂的DNA，二则用来募集DNA修复蛋白，为完成DNA修复的功能打基础。<br>明白了PARP，那么PARP抑制剂又是怎么起效的呢？<br>前面说了PARP是修损伤和断裂DNA的。这时候如果有PARP抑制剂，就会把PARP和受损的DNA分离，导致DNA修复停滞。卡壳之后，DNA总这么断着也不行，于是细胞内部就开启了同源重组修复(Homologous Recombination Repair)——简称HRR——来解决PARP罢工的问题。<br><img src="https://p.ipic.vip/1qvren.jpg" alt="PARP抑制剂机制示意图"><br>HRR这个团队有几个核心骨干，打头阵的就是BRCA（乳腺癌易感基因）蛋白，如果这时候有BRCA蛋白表达正常，细胞就恢复修复DNA，继续存活。但如果这时候有BRCA突变，那么HRR也就停摆了，DNA都不正常了，那么细胞也就离死不远了。<br>因此，当肿瘤细胞有BRCA突变的时候，同源重组团队歇菜，这时候再来点PARP抑制剂，双管齐下让肿瘤细胞DNA无法修复，就可以让肿瘤细胞精准凋亡。这个双管齐下有个专门的术语，叫做“合成致死”。<br>PARP抑制剂目前主要用于卵巢癌治疗缓解后的维持治疗，但亦可用于胚系BRCA突变的复发性卵巢癌的后线治疗。</p>
<h5 id="言归正传，继续DUO-O研究的物语。"><a href="#言归正传，继续DUO-O研究的物语。" class="headerlink" title="言归正传，继续DUO-O研究的物语。"></a>言归正传，继续DUO-O研究的物语。</h5><p>单从名字上看DUO是二重奏的意思，也是指度伐利尤单抗（Durvalumab），后面的O是指PARP抑制剂奥拉帕利（Olaparib），DUO-O连起来就是度伐利尤单抗+奥拉帕利的联合用药。<br>DUO-O是一项临床III期随机对照研究，这次ASCO会议报告的事中期分析结果，共入选了1130例新诊断 III或IV期、高级别上皮性、非BRCA突变的卵巢癌患者。<br>由于<a class="link"   target="_blank" rel="noopener" href="https://ascopost.com/news/june-2023/addition-of-olaparib-and-durvalumab-to-standard-of-care-may-prolong-progression-free-survival-in-patients-with-advanced-ovarian-cancer/" >研究分了三组<i class="fas fa-external-link-alt"></i></a>，感兴趣的朋友可以点看文稿对照着研究设计图来看，不看听我说也没关系。DUO-O研究的受试者均接受标准治疗：即是用紫杉醇&#x2F;卡铂化疗加贝伐单抗，随后进行贝伐单抗维持治疗15个月，这也是组1（n&#x3D;378）——即对照组的治疗方案。对第2组（n&#x3D;374）和第3组（n&#x3D;378）的患者，都在初始化疗阶段添加了度伐利尤单抗联合化疗，并在后续的维持治疗方案中继续使用24个月。对于第3组的患者，在第二组的基础上添加了奥拉帕利到维持治疗方案中。分组虽然复杂，您只需记住第三组是奥拉帕利+度伐利尤单抗联合组，第一组是空白对照就行了。<br><img src="https://p.ipic.vip/oajdla.png" alt="DUO-O研究的分组方案"><br>结果方面，本次会议上DUO-O研究公布了多项结果，其中主要有两个我认为比较关键，首先来看看上述意向治疗三分组结果。<br>从生存曲线图中可以看出，三组中位数PFS相比是逐渐延长的（19.3个月 vs 20.6个月 vs 24.2个月），也就是联合治疗确实优于了单一治疗，而且三联优于两联。<br><img src="https://p.ipic.vip/ex7eww.png" alt="ITT人群三组PFS比较"><br>奥拉帕利+度伐利尤单抗组（组3）的中位数无进展生存期为24.2个月，显著优于对照组（组1）的19.3个月（p&lt;0.0001），相比对照组（组1）肿瘤进展风险降低了37%。<br><img src="https://p.ipic.vip/imbj6h.png" alt="组1 vs 组3 PFS结果"><br>因为前述PARP抑制剂对有同源修复障碍的患者疗效更好，那么对同源修复障碍阳性亚组进行观察，更能明确加用PARP抑制剂的治疗意义。最终这个亚组结果和我们预想的一样，即度伐利尤单抗加奥拉帕利组肿瘤进展的风险比对照组患者降低了51%，的确高于总体人群，提示PARP抑制剂对有同源修复障碍的患者是有明确额外作用的。<br><img src="https://p.ipic.vip/79xtw8.png" alt="HRD阳性人群中 PARPi+PDL1i vs 对照结果"><br>安全性方面，约90%的患者完成了试验方案。三组报告的不良反应率分别为34%、43% 和 39%；最常见的是中性粒细胞减少症，三组间发生率差别不大。</p>
<h5 id="最后聊聊我对DUO-O研究的一些看法："><a href="#最后聊聊我对DUO-O研究的一些看法：" class="headerlink" title="最后聊聊我对DUO-O研究的一些看法："></a>最后聊聊我对DUO-O研究的一些看法：</h5><p>我去年采访吴小华教授，他提及卵巢癌有几个70%，其中一个70%的患者会在术后复发；所以卵巢癌的维持治疗就显得非常重要，但手段却相对有限，所以DUO-O带来的综合疗法，把能用的都用上了，应该说代表了目前肿瘤界卵巢癌治疗的金字塔尖了，三英确实战胜了吕布，而且取得的进步也的确可以称为“巨大”，这对于晚期卵巢癌患者来说无疑是一个福音，特别是那些有同源重组修复障碍的患者。<br>此外，吴教授还提及中国的卵巢癌患者中有将近28%的患者有BRCA的突变，也就是说超过70%的卵巢癌也不含有BRCA突变。所以DUO-O纳入的无BRCA突变则是代表了大多数的卵巢癌人群，无疑也扩展了PARP抑制剂的使用场景。<br>另外，既往卵巢癌对免疫治疗是大门紧闭，但DUO-O研究给免疫治疗开了一扇窗， 虽然目前还并不清楚度伐利尤单抗在联合治疗中的确切作用。<br>此外，度伐利尤单抗+奥拉帕利方案也并非只在卵巢癌这一处开花，近年来，在小细胞肺癌（<a class="link"   target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/37146473/" >MEDIOLA小细胞肺癌研究<i class="fas fa-external-link-alt"></i></a>）、乳腺癌（<a class="link"   target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/32771088/" >MEDIOLA转移性乳腺癌研究<i class="fas fa-external-link-alt"></i></a>）、尿路上皮癌（<a class="link"   target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/35737919/" >BATOU研究<i class="fas fa-external-link-alt"></i></a>）等肿瘤中也有涉及，也都有一定的获益，只是局限在小规模的试验阶段。<br>本期特别篇就到这里了，我是李静，感谢您的收听，我们下期见。</p>

            </div>

            
                <div class="post-copyright-info">
                    
<div class="article-copyright-info-container">
    <ul class="copyright-info-content">
        <li class="post-title">
            <span class="type">Post title</span>: <span class="content">ASCO23特别篇之研究物语： DUO-O研究--D医生投稿</span>
        </li>
        <li class="post-author">
            <span class="type">Post author</span>: <span class="content">肿瘤界</span>
        </li>
        <li class="post-time">
            <span class="type">Create time</span>: <span class="content">2023-07-17 10:13:28</span>
        </li>
        <li class="post-link">
            <span class="type">Post link</span>: <span class="content">2023/07/17/ASCO23特别篇之研究物语： DUO-O研究--D医生投稿/</span>
        </li>
        <li class="post-license">
            <span class="type">Copyright notice</span>: <span class="content">All articles in this blog are licensed under <a class="license" target="_blank" rel="noopener" href="https://creativecommons.org/licenses/by-nc-sa/4.0/deed.zh">BY-NC-SA</a> unless stating additionally.</span>
        </li>
    </ul>
    <div class="copy-copyright-info flex-center tooltip" data-content="Copy copyright info" data-offset-y="-2px">
        <i class="fa-solid fa-copy"></i>
    </div>
</div>

                </div>
            

            

            
                <div class="article-nav">
                    
                        <div class="article-prev">
                            <a class="prev"
                               rel="prev"
                               href="/zlj_submit/2023/07/17/ASCO23%E7%89%B9%E5%88%AB%E7%AF%87%E4%B9%8B%E7%A0%94%E7%A9%B6%E7%89%A9%E8%AF%AD%EF%BC%9AHERIZON-BTC-01%E7%A0%94%E7%A9%B6--O%E5%8C%BB%E7%94%9F%E6%8A%95%E7%A8%BF/"
                            >
                            <span class="left arrow-icon flex-center">
                              <i class="fas fa-chevron-left"></i>
                            </span>
                                <span class="title flex-center">
                                <span class="post-nav-title-item">ASCO23特别篇之研究物语：HERIZON-BTC-01研究--O医生投稿</span>
                                <span class="post-nav-item">Prev posts</span>
                            </span>
                            </a>
                        </div>
                    
                    
                        <div class="article-next">
                            <a class="next"
                               rel="next"
                               href="/zlj_submit/2023/07/17/ASCO23%20%E7%89%B9%E5%88%AB%E7%AF%87%E4%B9%8B%E7%A0%94%E7%A9%B6%E7%89%A9%E8%AF%AD%EF%BC%9ANATALEE%E7%A0%94%E7%A9%B6--V%E5%8C%BB%E7%94%9F%E6%8A%95%E7%A8%BF/"
                            >
                            <span class="title flex-center">
                                <span class="post-nav-title-item">ASCO23 特别篇之研究物语：NATALEE研究--V医生投稿</span>
                                <span class="post-nav-item">Next posts</span>
                            </span>
                                <span class="right arrow-icon flex-center">
                              <i class="fas fa-chevron-right"></i>
                            </span>
                            </a>
                        </div>
                    
                </div>
            

            
        </div>

        
    </div>
</div>


                
            </div>

        </div>

        <div class="page-main-content-bottom">
            
<footer class="footer">
    <div class="info-container">
        <div class="copyright-info info-item">
            &copy;
            
                <span>2020</span> -
            
            2023
            
                &nbsp;<i class="fas fa-heart icon-animate"></i>
                &nbsp;<a href="/">肿瘤界</a>
            
        </div>
        
        <div class="theme-info info-item">
            Powered by <a target="_blank" href="https://hexo.io">Hexo</a>&nbsp;|&nbsp;Theme&nbsp;<a class="theme-version" target="_blank" href="https://github.com/XPoet/hexo-theme-keep">Keep v3.6.1</a>
        </div>
        
        
    </div>
</footer>

        </div>
    </div>

    
        <div class="post-tools">
            <div class="post-tools-container">
    <ul class="tools-list">
        <!-- TOC aside toggle -->
        

        <!-- go comment -->
        
    </ul>
</div>

        </div>
    

    <div class="right-bottom-side-tools">
        <div class="side-tools-container">
    <ul class="side-tools-list">
        <li class="tools-item tool-font-adjust-plus flex-center">
            <i class="fas fa-search-plus"></i>
        </li>

        <li class="tools-item tool-font-adjust-minus flex-center">
            <i class="fas fa-search-minus"></i>
        </li>

        <li class="tools-item tool-dark-light-toggle flex-center">
            <i class="fas fa-moon"></i>
        </li>

        <!-- rss -->
        

        
            <li class="tools-item tool-scroll-to-top flex-center">
                <i class="fas fa-arrow-up"></i>
            </li>
        

        <li class="tools-item tool-scroll-to-bottom flex-center">
            <i class="fas fa-arrow-down"></i>
        </li>
    </ul>

    <ul class="exposed-tools-list">
        <li class="tools-item tool-toggle-show flex-center">
            <i class="fas fa-cog fa-spin"></i>
        </li>
        
    </ul>
</div>

    </div>

    <div class="zoom-in-image-mask">
    <img class="zoom-in-image">
</div>


    
        <div class="search-pop-overlay">
    <div class="popup search-popup">
        <div class="search-header">
          <span class="search-input-field-pre">
            <i class="fas fa-keyboard"></i>
          </span>
            <div class="search-input-container">
                <input autocomplete="off"
                       autocorrect="off"
                       autocapitalize="off"
                       placeholder="Search..."
                       spellcheck="false"
                       type="search"
                       class="search-input"
                >
            </div>
            <span class="close-popup-btn">
                <i class="fas fa-times"></i>
            </span>
        </div>
        <div id="search-result">
            <div id="no-result">
                <i class="fas fa-spinner fa-pulse fa-5x fa-fw"></i>
            </div>
        </div>
    </div>
</div>

    

</main>




<script src="/zlj_submit/js/utils.js"></script>

<script src="/zlj_submit/js/main.js"></script>

<script src="/zlj_submit/js/header-shrink.js"></script>

<script src="/zlj_submit/js/back2top.js"></script>

<script src="/zlj_submit/js/dark-light-toggle.js"></script>





    
<script src="/zlj_submit/js/local-search.js"></script>







<div class="post-scripts">
    
        
<script src="/zlj_submit/js/post-helper.js"></script>

        
        
    
</div>



</body>
</html>
